Literature DB >> 15328140

Convenient biological assay for polyethylene glycol-interferons in patients with hepatitis C.

Anne Boulestin1, Nassim Kamar, Florence Legrand-Abravanel, Karine Sandres-Saune, Laurent Alric, Jean-Pierre Vinel, Lionel Rostaing, Jacques Izopet.   

Abstract

The vesicular stomatitis virus cytopathic effect reduction assay is suitable to quantify polyethylene glycol-alpha interferon 2a (PEG-IFN-alpha 2a) and PEG-IFN-alpha 2b. Human serum and ribavirin did not interfere with the assay. This bioassay was successfully used for assaying PEG-IFN-alpha 2a and PEG-IFN-alpha 2b in serum samples from patients undergoing combination therapy.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15328140      PMCID： PMC514722          DOI： 10.1128/AAC.48.9.3610-3612.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  12 in total

Review 1.  Predicting antiviral treatment response in chronic hepatitis C: how accurate and how soon?

Authors:  Samuel S Lee; Ayman A Abdo
Journal:  J Antimicrob Chemother       Date:  2003-03       Impact factor: 5.790

2.  Early intrathecal synthesis of interferon in herpes encephalitis.

Authors:  P Lebon; G Ponsot; J Aicardi; F Goutières; M Arthuis
Journal:  Biomedicine       Date:  1979-12

3.  Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

Authors:  P Glue; J W Fang; R Rouzier-Panis; C Raffanel; R Sabo; S K Gupta; M Salfi; S Jacobs
Journal:  Clin Pharmacol Ther       Date:  2000-11       Impact factor: 6.875

4.  Establishment of new and replacement World Health Organization International Biological Standards for human interferon alpha and omega.

Authors:  A Meager; R Gaines Das; K Zoon; A Mire-Sluis
Journal:  J Immunol Methods       Date:  2001-11-01       Impact factor: 2.303

5.  A pharmacokinetic model for alpha interferon administered subcutaneously.

Authors:  E Chatelut; L Rostaing; N Grégoire; J L Payen; A Pujol; J Izopet; G Houin; P Canal
Journal:  Br J Clin Pharmacol       Date:  1999-04       Impact factor: 4.335

6.  Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy.

Authors:  J Izopet; J L Payen; L Alric; K Sandres; J P Charlet; J P Vinel; M Duffaut; J P Pascal; J Puel
Journal:  J Med Virol       Date:  1998-02       Impact factor: 2.327

7.  Experimental study of transplacental passage of alpha interferon by two assay techniques.

Authors:  A Waysbort; M Giroux; V Mansat; M Teixeira; J C Dumas; J Puel
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

8.  Ribavirin quantification in combination treatment of chronic hepatitis C.

Authors:  Sylvie Larrat; Françoise Stanke-Labesque; Agnès Plages; Jean-Pierre Zarski; Germain Bessard; Claude Souvignet
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.

Authors:  Jan M Vrolijk; Artur Kaul; Bettina E Hansen; Volker Lohmann; Bart L Haagmans; Solko W Schalm; Ralf Bartenschlager
Journal:  J Virol Methods       Date:  2003-06-30       Impact factor: 2.014

10.  Genetic heterogeneity of the NS5A gene of hepatitis C virus and early response to interferon-alpha.

Authors:  Anne Boulestin; Karine Sandres-Saune; Jean-Louis Payen; Lionel Rostaing; Christophe Pasquier; Jacques Izopet
Journal:  J Infect Dis       Date:  2003-10-13       Impact factor: 5.226
View more
  2 in total

1.  Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.

Authors:  Cédric Laouénan; Patrick Marcellin; Martine Lapalus; Feryel Khelifa-Mouri; Nathalie Boyer; Fabien Zoulim; Lawrence Serfaty; Jean-Pierre Bronowicki; Michelle Martinot-Peignoux; Olivier Lada; Tarik Asselah; Céline Dorival; Christophe Hézode; Fabrice Carrat; Florence Nicot; Gilles Peytavin; France Mentré; Jeremie Guedj
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

2.  Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation.

Authors:  Catherine François; Isabelle Bernard; Sandrine Castelain; Bryan Charleston; Martin D Fray; Jean-Claude Capiod; Gilles Duverlie
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.